Trial Profile
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Tolerability and Efficacy of AMG 145 on Low-Density Lipoprotein Cholesterol (LDL-C) in Subject With Heterozygous Familial Hypercholesterolemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Evolocumab (Primary) ; Ezetimibe; HMG-CoA reductase inhibitors
- Indications Hyperlipoproteinaemia type IIa
- Focus Therapeutic Use
- Acronyms RUTHERFORD
- Sponsors Amgen
- 01 Mar 2017 Results (n=6026) of pooled safety analysis of this and other eleven trials (LAPLACE-TIMI 57,RUTHERFORD,GAUSS,MENDEL,YUKAWA,LAPLACE-2,RUTHERFORD-2,GAUSS-2,MENDEL-2,DISCARTES,THOMAS-1,THOMAS-2) published in the Circulation.
- 04 Sep 2013 Results from a pooled efficacy analysis presented at the ESC Congress 2013: Annual Congress of the European Society of Cardiology.
- 04 Sep 2013 Pooled tolerability analysis presented at the ESC Congress 2013: Annual Congress of the European Society of Cardiology.